82 results match your criteria Transurethral Needle Ablation of the Prostate TUNA


Prospective short-term evaluation of transurethral needle ablation procedure in an ambulatory setting.

Urol Int 2012 26;89(4):451-6. Epub 2012 Oct 26.

Urology Department, Tenon Hospital, 4 rue de la Chine, Paris Cedex 20, France.

Objective: To assess the results of transurethral needle ablation (TUNA) (Prostiva®, Medtronic, France) performed in an ambulatory setting in men with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Materials And Methods: A multicenter open-label study was conducted. Short-term success was defined by ability to leave the hospital on the evening of the intervention, and absence of rehospitalization due to complications during the first postoperative month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000342362DOI Listing
May 2013
18 Reads
1.151 Impact Factor

Effects of pulsed electromagnetic fields on benign prostate hyperplasia.

Int Urol Nephrol 2011 Dec 3;43(4):955-60. Epub 2011 May 3.

Urological Clinic, University Hospital, Faculty of Medicine, University of Ioannina, Ioannina, Greece.

Introduction: Benign prostate hyperplasia (BPH) has been treated with various types of electromagnetic radiation methods such as transurethral needle ablation (TUNA), interstitial laser therapy (ILC), holmium laser resection (HoLRP). In the present study, the effects of a noninvasive method based on the exposure of patients with BPH to a pulsative EM Field at radiofrequencies have been investigated.

Materials And Methods: Twenty patients with BPH, aging 68-78 years old (y. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11255-011-9944
Web Search
http://link.springer.com/10.1007/s11255-011-9944-7
Publisher Site
http://dx.doi.org/10.1007/s11255-011-9944-7DOI Listing
December 2011
24 Reads
1.293 Impact Factor

[Transurethral needle ablation Prostiva for treating symptomatic benign prostatic hyperplasia: a review].

Prog Urol 2010 Sep 29;20(8):566-71. Epub 2010 Jun 29.

Service d'urologie, hôpital Cochin Port-Royal, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

Benign prostatic hyperplasia (BPH) is a common disease affecting a large proportion of men older than 50 years. There are multiple treatment options for BPH including medications, minimally invasive options such as transurethral needle ablation (Tuna) and transurethral microwave therapy (TUMT), and more invasive options such as transurethral laser vaporization and transurethral resection of the prostate (TURP). The minimally invasive options induce thermal injury to the BPH adenoma with a lower risk of permanent side effects than TURP. Read More

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S116670871000167
Publisher Site
http://dx.doi.org/10.1016/j.purol.2010.05.003DOI Listing
September 2010
4 Reads

Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature.

Can J Urol 2010 Aug;17(4):5249-54

Department of Urology, New York University Hospital, New York, New York 10016, USA.

Background: Transurethral resection of the prostate (TURP) has been the gold standard of the treatment of benign prostatic hyperplasia (BPH). In recent years there has been a significant shift in the treatment of BPH and guidelines emphasize minimally invasive surgery as a new treatment option. Minimal invasive technologies (MITs), such as transurethral microwave thermotherapy (TUMT), laser ablations, transurethral needle ablation (TUNA) have emerged as an alternative to the TURP. Read More

View Article

Download full-text PDF

Source
August 2010
4 Reads

[Prostatic calculi: silent stones].

Actas Urol Esp 2010 Jun;34(6):555-9

Servicio de Urología, Facultad de Medicina de la Universidad de Başkent, Turquía.

Introduction And Objectives: Prostate stones are frequently encountered during transurethral resection of the prostate in urology practice. We aimed to demonstrate the physical and chemical properties of prostate stones. We also aimed to determine possible relationship between inflammation of prostate gland and prostate stones. Read More

View Article

Download full-text PDF

Source
June 2010
3 Reads

The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review.

Asian J Androl 2010 Jul 17;12(4):500-8. Epub 2010 May 17.

Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.

A systematic review of randomized controlled trials and cohort studies was conducted to evaluate data for the effects of minimally invasive procedures for treatment of symptomatic benign prostatic hyperplasia (BPH) on male sexual function. The studies searched were trials that enrolled men with symptomatic BPH who were treated with laser surgeries, transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), transurethral ethanol ablation of the prostate (TEAP) and high-intensity frequency ultrasound (HIFU), in comparison with traditional transurethral resection of the prostate (TURP) or sham operations. A total of 72 studies were identified, of which 33 met the inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://www.asiaandro.com/Abstract.asp?doi=10.1038/aja.2010.3
Publisher Site
http://dx.doi.org/10.1038/aja.2010.33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739367PMC
July 2010
7 Reads

Minimally invasive surgery in the management of benign prostatic hyperplasia.

Minerva Urol Nefrol 2009 Sep;61(3):269-89

Division of Urology, University of Texas Medical School at Houston, Houston, TX 77030, USA.

Unlabelled: Benign prostatic hyperplasia (BPH) is a chronic and often progressive condition, affecting the majority of men by the seventh decade of life. The historical gold standard has been transurethral resection of prostate (TURP), an effective procedure still associated with risk of bleeding, TUR syndrome, and need for general anesthetic and hospitalization. Minimally Invasive Surgical Techniques aim to address these limitations by offering lower morbidity, reducing hospitalization, and increasing convenience. Read More

View Article

Download full-text PDF

Source
September 2009
6 Reads

Update in minimal invasive therapy in benign prostatic hyperplasia.

Minerva Urol Nefrol 2009 Sep;61(3):257-68

Department of Urology, Canisius Wilhemina Hospital, Nijmegen, The Netherlands.

Last decade several new treatment modalities for minimal invasive therapy of benign prostatic hyperplasia have been developed, both ablative and non-ablative. In this review the authors describe the different techniques and clinical studies of bipolar transurethral resection of the prostate (TURP), transurethral resection in saline (TURis), the different laser therapies for the prostate, transurethral microwave thermotherapy (TUMT), high intensity focused ultrasound (HIFU), transurethral needle ablation (TUNA), hot water induced thermotherapy (WIT), prostatic stents, intraprostatic ethanol injections and botulinum toxin A injections. The different bipolar systems and photoselective vaporisation might replace the ''gold standard'', monopolar TURP, in the near future. Read More

View Article

Download full-text PDF

Source
September 2009
5 Reads

[Two-years follow-up of radiofrequency thermotherapy for urination disorders due to benign prostatic hyperplasia].

Prog Urol 2009 Jul 17;19(7):501-6. Epub 2009 May 17.

Hôpital Sainte-Marguerite, 4, boulevard A.-Laveran, BP 50, 13998 Marseille Armées, France.

Aim: To describe medium-term functional results of Transurethral Needle Ablation (TUNA) to treat symptomatic benign prostatic hyperplasia (BPH) refractory to medical treatment.

Materials And Method: Patients who completed at least 2 years follow-up after TUNA were systematically offered a reevaluation including: Flowmetry, PSA, symptom score (IPSS), satisfaction index visual analogic scale (VAS) and a treatment impact evaluation with a Likert scale (ranging from much worse to much improved).

Results: From December 2002 to January 2007, 45 patients were treated with TUNA under local regional anaesthesia (prostatic block). Read More

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S116670870900096
Publisher Site
http://dx.doi.org/10.1016/j.purol.2009.03.004DOI Listing
July 2009
2 Reads

[Treatment of benign prostatic hyperplasia by radiofrequency (TUNA): a monocentric study of 28 cases treated in ambulatory surgery].

Prog Urol 2009 May 18;19(5):327-32. Epub 2008 Dec 18.

Service d'urologie, CHU de Caen, Caen, France.

Aim: To assess the feasibility of ambulatory surgery in the treatment of benign prostatic hyperplasia using radio frequency (TUNA) and evaluate its place in terms of efficiency among other minimally invasive surgical techniques.

Method: Fifty-four patients suffering from benign prostatic hyperplasia and for whom medical treatment was ineffective, were treated with radio frequency between September 2004 and June 2007. Among them, 28 patients, whose average age was 65. Read More

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S116670870800520
Publisher Site
http://dx.doi.org/10.1016/j.purol.2008.10.016DOI Listing
May 2009
4 Reads

Characterizing Prostiva RF treatments of the prostate for BPH with gadolinium-enhanced MRI.

ScientificWorldJournal 2009 Jan 18;9:10-6. Epub 2009 Jan 18.

Department of Urology, University of Chile, Santiago, Chile.

Transurethral needle ablation (TUNA) is an accepted and effective therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Prostiva (Medtronic, Shoreview, MN) is the newest-generation device, which includes a new needle design and radio frequency (RF) generator. This device creates temperatures of 120 degrees C and necrotic lesions in less than 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1100/tsw.2009.4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823118PMC
January 2009
6 Reads

Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement.

Health Technol Assess 2008 Nov;12(35):iii, ix-x, 1-146, 169-515

Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK.

Objectives: To determine the clinical effectiveness and cost utility of procedures alternative to TURP (transurethral resection of the prostate) for benign prostatic enlargement (BPE) unresponsive to expectant, non-surgical treatments.

Data Sources: Electronic searches of 13 databases to identify relevant randomised controlled trials (RCTs).

Review Methods: Two reviewers independently assessed study quality and extracted data. Read More

View Article

Download full-text PDF

Source
November 2008
5 Reads

Characterizing TUNA ablative treatments of the prostate for benign hyperplasia with gadolinium-enhanced magnetic resonance imaging.

J Endourol 2007 Nov;21(11):1361-6

Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.

Background And Purpose: Transurethral Needle Ablation of the prostate TUNA has been accepted as an office-based treatment for benign prostatic hyperplasia (BPH) for many years. Clinical outcomes have been reported, but the amount and location of the necrosis produced have yet to be characterized. The necrosis caused by TUNA was evaluated by gadolinium-enhanced magnetic resonance imaging (MRI) of the pelvis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/end.2007.0029DOI Listing
November 2007
6 Reads

[Advances in minimally invasive treatment of benign prostatic hyperplasia].

Authors:
Bin Yu Zhong Wang

Zhonghua Nan Ke Xue 2007 Aug;13(8):739-43

Department of Urology, the Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.

The therapeutic options for benign prostatic hyperplasia (BPH) can be divided into medicinal, surgical and minimally invasive treatments. The minimally invasive treatment of BPH is gradually accepted by more and more urologists for its advantages of less damage, good effect, quick recovery and easy acceptance by patients, which includes transurethral needle ablation of the prostate (TUNA), transurethral microwave therapy (TUMT), photoselective laser vaporization of the prostate (PVP), holmium laser enucleation of the prostate (HOLEP) and so on. This article updates the advances in the minimally invasive treatment. Read More

View Article

Download full-text PDF

Source
August 2007
2 Reads

[Benign prostatic hyperplasia: surgical treatment].

MMW Fortschr Med 2007 Aug;149(33-34):34-6

Klinik und Poliklinik für Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.

According to the current treatment algorithm, surgical treatment of benign prostatic syndrome (BPS) is the next step after a pharmacological treatment. In addition to conventional transurethral resection of the prostate (TURP), much interest is shifting towards alternative sugical techniques such as transurethral microwave therapy (TUMT),transurethral needle ablation of the prostate (TUNA) and several laser techniques. Read More

View Article

Download full-text PDF

Source
August 2007
3 Reads

[Evaluation of radiofrequency (TUNA) in the outpatient treatment of benign prostatic hyperplasia].

Prog Urol 2007 Jun;17(4):824-7

Service d'Urologie du CHU de Caen, Caen, France.

Objective: Evaluating the effectiveness and feasibility of transurethral needle ablation (TUNA) for young patients with symptomatic benign hyperplasia (BPH) in outpatient care.

Material And Methods: From 2004 to 2005, 9 patients (mean age: 59.7 years) were treated with the TUNA device. Read More

View Article

Download full-text PDF

Source
June 2007
4 Reads

Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary.

Curr Med Res Opin 2007 Jul;23(7):1715-32

Urology Complex Structure, Department of Surgery, Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia, Italy.

Background And Scope: Despite the high prevalence and huge socio-economic impact of benign prostatic hyperplasia (BPH) in Italy, no national guidelines have been produced so far. This is a summary of the first Italian guidelines on the diagnosis and treatment of lower urinary tract symptoms (LUTS) related to uncomplicated BPH, prepared by a multidisciplinary panel under the auspices of the Italian Association of Urologists and introduced in Italy in 2003. An update compiled by the authors is also included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079907X210534 DOI Listing
July 2007
17 Reads

Long-term results of three different minimally invasive therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: comparison at a single institute.

Int J Urol 2007 Apr;14(4):326-30

Department of Urology, School of Medicine, Keio University, Tokyo, Japan.

Objective: We analyzed the efficacy and durability of three different minimally invasive therapies (MIT) for lower urinary symptoms performed at a single institution based on a 5-year prospective cohort study.

Methods: The pre- and postoperative evaluation was made in 103 patients with the following three MIT options: (i) transurethral microwave thermotherapy (TUMT, n = 34); (ii) transurethral needle ablation (TUNA, n = 29); and (iii) transrectal high intensity focused ultrasound (HIFU, n = 40).

Results: All three treatments significantly improved the symptom scores up to 2 years after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1442-2042.2007.01692.xDOI Listing
April 2007
5 Reads

Is the minimally invasive treatment as good as transurethral resection for benign prostatic hyperplasia?

Int Urol Nephrol 2007 2;39(1):161-8. Epub 2007 Mar 2.

Division of Urology, Hospital Israelita Albert Einstein, Unicamp R. Augusta 2347, 3o andar, 01413-000 São Paulo, Brazil.

Despite the development of new technologies, transurethral resection of the prostate (TURP) is still considered the gold standard for surgical treatment of the benign prostate hyperplasia (BPH). In general, new minimally invasive treatments have not demonstrated better outcomes than TURP in evidence based medicine trials published to date, and should be reserved for patients who prefer to avoid surgery, who are unsuitable candidates for surgery or who no longer respond favorably to medication. TUMT and TUNA appears to be more effective than medical therapy but less effective than TURP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-006-9053-1DOI Listing
November 2007
3 Reads

How do I treat and follow my TUNA patients.

World J Urol 2006 Sep 21;24(4):397-404. Epub 2006 Jul 21.

Department of Urology, Erasme Hospital, Brussels University Clinics, 808 route de Lennik, 1070, Brussels, Belgium.

Transurethral needle ablation (TUNA) of the prostate is an alternative treatment for benign prostatic hyperplasia (BPH) generating temperatures around 100 degrees C leading to necrotic lesions inside the prostate. TUNA is a minimally invasive, low morbidity associated, approach that uses radiofrequency energy. The needles are covered by teflon shields that protect the urethra from thermal injury. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-006-0091-1
Publisher Site
http://dx.doi.org/10.1007/s00345-006-0091-1DOI Listing
September 2006
7 Reads

Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia.

BMC Urol 2006 Jun 21;6:14. Epub 2006 Jun 21.

Agency for Health Technology Assessment, Ministry of Health & Consumers Affairs, Sinesio Delgado 4, 28029 Madrid, Spain.

Background: Benign prostatic hyperplasia (BPH) constitutes a major clinical problem. Minimally invasive therapies for the treatment of symptomatic BPH include Transurethral Needle Ablation (TUNA), but it is unclear what impact this technique has on the disease and its role among other currently available therapeutic options. The objective of this study is to ascertain the efficacy and safety of TUNA in the treatment of BPH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2490-6-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538609PMC
June 2006
6 Reads

[Benign prostatic syndrome (BPS). Ablative treatments].

Urologe A 2006 Jun;45(6):769-80; quiz 781-2

Urologische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, 81377 , München,

Today, the surgical treatment of the benign prostatic syndrome (BPS) often follows a course of drug treatment. Besides conventional transurethral resection of the prostate (TURP), which has represented the standard therapeutic option for decades, and its in part significant modifications ("vaporizing resection"; bipolar resection), much of the interest has shifted to alternative instrumental procedures like transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA) or several laser techniques. By reviewing the current literature, preferably from randomized controlled trials, these different procedures are critically assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-006-1039-1DOI Listing
June 2006
2 Reads

Unequal use of new technologies by race: the use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries.

J Urol 2006 May;175(5):1830-5; discussion 1835

Division of Health Services Research and Policy, University of Minnesota School of Public Health, Minneapolis, Minnesota 55455, USA.

Purpose: We compared the availability and use of transurethral microwave therapy, transurethral needle ablation, contact or noncontact laser therapy and transurethral resection of the prostate among elderly black and white Medicare beneficiaries.

Materials And Methods: We examined 100% Medicare Inpatient, Outpatient, Carrier and Denominator files of men 65 years old or older who underwent these procedures in 1999 through 2001. White-to-black race rate ratios for each procedure were computed for the entire United States, as well as for a restricted set of counties in which procedures were available to black beneficiaries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0022-5347(05)00997-3DOI Listing
May 2006
3 Reads

[Treatment of benign prostatic hyperplasia (BPH) by transurethral needle ablation (TUNA) and 36-month follow-up of the retreatment rate].

Prog Urol 2005 Sep;15(4):674-80

Service d'Urologie, Hôpital Edouard Herriot, Lyon, France.

Objective: Benign prostatic hyperplasia (BPH) is a disease affecting about 25% of men over the age of 40. One half of these men report symptoms that interfere with their daily activities.

Material And Methods: In this multicentre study, 102 patients with BPH were treated by transurethral needle ablation (TUNA). Read More

View Article

Download full-text PDF

Source
September 2005
8 Reads

Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.

Authors:

Ont Health Technol Assess Ser 2006 1;6(17):1-121. Epub 2006 Aug 1.

Objective: The Ontario Health Technology Advisory Committee asked the Medical Advisory Secretariat (MAS) to conduct a health technology assessment on energy delivery systems for the treatment of benign prostatic hyperplasia (BPH).

Clinical Need: TARGET POPULATION AND CONDITION BPH is a noncancerous enlargement of the prostate gland and the most common benign tumour in aging men. (1) It is the most common cause of lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) and is an important cause of diminished quality of life among aging men. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379165PMC
October 2012
48 Reads

Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer.

Pathol Res Pract 2005 ;201(8-9):593-8

Department of Urology, Dokuz Eylul University School of Medicine, Izmir, Turkey.

The aim of the study was to investigate immunohistochemically the expression of vascular endothelial growth factor (VEGF) in untreated and androgen-deprived patients with prostate cancer. The study included 20 patients with prostate cancer who had undergone transurethral prostatectomy due to infravesical obstruction. All patients had been receiving androgen deprivation therapy for at least 3 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2005.07.003DOI Listing
November 2005
9 Reads

[Transurethral ablation (Precision Plus) in the treatment of patients with benign prostatic hyperplasia].

Urologiia 2005 May-Jun(3):12-5

Benign prostatic hyperplasia (BPH) is a common condition among elderly men. Transurethral needle ablation of the prostate (TUNA) is a minimally invasive procedure for treatment of BPH. With TUNA, the inner region of the prostate is selectively ablated with temperatures approaching 90-100 degrees C while prostatic urothelium is preserved. Read More

View Article

Download full-text PDF

Source
September 2005
4 Reads

A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.

J Urol 2005 Jun;173(6):2090-3; discussion 2093

Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Purpose: We performed an analysis comparing the cost of medical management with TUNA therapy for a 5-year period.

Materials And Methods: Published costs for tamsulosin, finasteride, transurethral needle ablation (TUNA, Medtronic, Inc., Minneapolis, Minnesota) and transurethral resection of the prostate were used to construct a cost analysis model comparing medication with TUNA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000158451.30419.66DOI Listing
June 2005
3 Reads

A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia.

BJU Int 2004 Jul;94(1):83-8

Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.

Objectives: To investigate the short- and long-term effectiveness of transurethral needle ablation (TUNA) of the prostate for clinical benign prostatic hyperplasia (BPH), using a meta-analysis of all clinical studies involving TUNA.

Methods: Data were extracted from two randomized trials, two non-randomized observational protocols and 10 single-arm studies conducted on TUNA, according to a determined protocol. The meta-analysis was based on the change in the mean score at the end of study from that at baseline. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1464-410X.2004.04906.x
Publisher Site
http://dx.doi.org/10.1111/j.1464-410X.2004.04906.xDOI Listing
July 2004
9 Reads

Transurethral resection versus minimally invasive treatments of benign prostatic hyperplasia: results of treatments. Our experience.

Arch Ital Urol Androl 2004 Mar;76(1):11-8

Institute of Urology, Polytechnic University of the Marche Region, Medical School, Ancona, Italy.

Objective: In this non-randomized prospective study the results of standard TURP (Transurethral Resection of the Prostate) versus other minimally invasive treatments were compared.

Materials And Methods: Among all the patients treated at our Institution for bladder outlet obstruction due to BPH (Benign Prostatic Hyperplasia) from January 1995 to June 1998, 212 patients have been evaluated; 90 patients underwent to TURP, 13 patients to TVP (Transurethral ElectroVaporization), 24 patients to TUNA (TransUrethral Needle Ablation), 71 patients to ILC (Interstitial Laser Coagulation), and 13 patients to WIT (Water-Induced Thermotherapy).

Results: TURP achieves the highest decrease of prostate volume (48. Read More

View Article

Download full-text PDF

Source
March 2004
10 Reads

Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

J Urol 2004 Jun;171(6 Pt 1):2336-40

Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Materials And Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54%) were randomly selected to receive TUNA and 56 (46%) were selected to receive TURP. Read More

View Article

Download full-text PDF

Source
June 2004
5 Reads

Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia.

Drugs Today (Barc) 1998 Apr;34(4):353-60

Division of Urology, Department of Surgery, University of Wisconsin, Hospital and Clinics, Madison, Wisconsin, USA.

A third era in the surgical treatment of benign prostatic hyperplasia (BPH) utilizes less invasive treatment modalities. Transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA) and a wide variety of laser treatments are the most conspicuous new treatment modalities approved or awaiting approval. In general, the alternative treatments produce less improvement in symptoms and peak urinary flow rates (Q(max)) than open prostatectomy or transurethral resection of the prostate (TURP), which remains the "gold standard". Read More

View Article

Download full-text PDF

Source
April 1998
4 Reads

Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA). Review of the literature and six years of clinical experience.

Urol Int 2004 ;72(1):32-9

Department of Urology, University of Cologne, Cologne, Germany.

Following FDA clearance and the establishment of Medicare coverage, transurethral needle ablation (TUNA) has become an established and widely-adopted treatment method for BPH in the USA. Germany is lagging behind at present, though a change can also be recognized there. The lack of long-term data has often been criticized. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/75270
Publisher Site
http://dx.doi.org/10.1159/000075270DOI Listing
June 2004
2 Reads

Therapeutic effect of transurethral needle ablation in non-bacterial prostatitis: chronic pelvic pain syndrome type IIIa.

Int J Urol 2004 Feb;11(2):97-102

Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Aim: Non-bacterial prostatitis is difficult to manage with conventional treatment. This study was undertaken to evaluate the therapeutic effect of transurethral needle ablation (TUNA) on men with chronic inflammatory non-bacterial prostatitis.

Methods: Thirty-two patients with non-bacterial prostatitis (type IIIa) were treated with TUNA. Read More

View Article

Download full-text PDF

Source
February 2004
4 Reads

[Current view and critic of alternatives to transurethral surgery of prostatic benign prostate].

Arch Esp Urol 2003 Nov;56(9):1023-32

Fundación Puigvert, C/Cartagena 340-350 08025 Barcelona, España.

Objectives: Critical update of transurethral surgery options based on the last decade most relevant bibliography.

Methods: Comparative study between Incision/TUR of the prostate and alternative techniques, accordingly to data from 30 randomized studies and 28 clinical studies. We evaluate efficiency, retreatment index, morbidity, post operative number of days with catheter, anesthetic requirements, and cost. Read More

View Article

Download full-text PDF

Source
November 2003
2 Reads

Variations of transition zone volume and transition zone index after transurethral needle ablation for symptomatic benign prostatic hyperplasia.

Int J Urol 2003 Jul;10(7):392-7

Departments of Urology, Nara Medical University, Nara, Japan.

Background: Transurethral needle ablation (TUNA) is less invasive than other therapies for benign prostatic hyperplasia (BPH) and produces coagulative necrosis within selected adenoma lesions. The action mechanism of TUNA is still obscure, even though many early studies have demonstrated good clinical results of TUNA. It is of interest and importance to know how TUNA influences the volume of the intraprostatic region responsible for bladder outlet obstruction in order to elucidate the anatomical action mechanism of TUNA. Read More

View Article

Download full-text PDF

Source
July 2003
4 Reads

Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers.

Eur Urol 2003 Jul;44(1):89-93

Department of Urology, Erasme Hospital, University Clinics of Brussels, 808 route de Lennik, B-1070 Brussels, Belgium.

Objective: TUNA has been demonstrated to be a safe and effective therapy for BPH. However the major criticism, as with all alternative treatments for BPH, was the lack of long-term data. We present the clinical outcome of patients treated by TUNA and followed for 5 years. Read More

View Article

Download full-text PDF

Source
July 2003
9 Reads

Radiofrequency Thermal Therapy for Benign Prostatic Hyperplasia by Transurethral Needle Ablation of the Prostate (TUNA): An Update.

Authors:
S E Myrick M Issa

Surg Technol Int 1998 ;7:309-14

Emory University School of Medicine.

View Article

Download full-text PDF

Source
October 2012
3 Reads

Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months.

J Endourol 2003 Mar;17(2):103-7

Department of Urology, Fatih University, School of Medicine, Ankara, Turkey.

Purpose: To compare the efficacy and safety of transurethral needle ablation (TUNA) and transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH) during an 18-months follow-up.

Patients And Methods: A series of 59 patients older than 40 years were included in this study. The entry criteria were prostate size <70 g, maximum urinary flow rate (Q(max)) <15 mL/sec, International Prostate Symptom Score (IPSS) >13, and no suspicion of prostate cancer according to the clinical or laboratory findings. Read More

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/08927790360587432
Publisher Site
http://dx.doi.org/10.1089/08927790360587432DOI Listing
March 2003
4 Reads

TUNA of the prostate in an office setting: nursing implications.

Urol Nurs 2003 Feb;23(1):33-9; quiz 40

Rhode Island Hospital, USA.

Transurethral needle ablation is a minimally invasive treatment for benign prostatic hyperplasia. The procedure, with emphasis on patient selection, preoperative preparation, nursing role during the treatment, as well as postoperative care and assessment, is discussed. Read More

View Article

Download full-text PDF

Source
February 2003
3 Reads

Minimally invasive therapies for benign prostatic hyperplasia.

World J Urol 2002 Sep 15;20(4):197-206. Epub 2002 Jun 15.

Department of Urology, University of California, Davis School of Medicine, Sacramento, CA 95817, USA.

A number of minimally invasive therapies have been studied in the last decade for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). Most of these utilize thermal energy to ablate the prostate. Paucity of long-term efficacy, safety and re-treatment rates are, however, the main concerns of all these forms of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-002-0283-2DOI Listing
September 2002
2 Reads

Transurethral needle ablation for the treatment of chronic pelvic pain syndrome (category III prostatitis): a randomized, sham-controlled study.

Urology 2002 Aug;60(2):300-4

Department of Surgery/Urology, Seinäjoki Central Hospital, Seinäjoki, Finland.

Objectives: To investigate the effectiveness and durability of transurethral needle ablation (TUNA) in the treatment of symptoms of chronic pelvic pain syndrome (CPPS) in a randomized, single-blind, sham-controlled study.

Methods: Thirty-three patients with moderate-to-severe symptoms of CPPS were randomized to either TUNA (n = 25) or urethrocystoscopy as a sham treatment (n = 8). The response to therapy was evaluated 3, 6, and 12 months after treatment using the Prostatitis Symptom Severity Index (PSSI), the International Prostate Symptom Score (IPSS), a visual analogue scale, and prostate volume, prostate-specific antigen, urinary flow, and residual urine volume measurements. Read More

View Article

Download full-text PDF

Source
August 2002
5 Reads

Transurethral needle ablation for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: outcome after 1 year.

J Endourol 2002 Mar;16(2):111-5

Department of Surgery, University of Bergen, Norway.

Purpose: The aims of the study were to evaluate short-term effects on lower urinary tract symptoms and uroflowmetry and assess side effects of transurethral needle ablation of the prostate (TUNA).

Patients And Methods: Twenty-six men with a median age 68 years (range 53-77 years) were evaluated with symptom scores and voiding parameters before and at 3 and 12 months after TUNA. All treatments were performed in the outpatient department using topical anesthesia supplemented with sedoanalgesia. Read More

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/089277902753619636
Publisher Site
http://dx.doi.org/10.1089/089277902753619636DOI Listing
March 2002
5 Reads

Transurethral needle ablation for chronic nonbacterial prostatitis.

BJU Int 2002 Feb;89(3):226-9

Department of Urology, Korea University College of Medicine, Seoul, Korea.

Objective: To investigate the efficacy of transurethral needle ablation (TUNA) of the prostate for treating chronic nonbacterial prostatitis unresponsive to conservative therapies.

Patients And Methods: Forty-two patients (mean age 38.5 years, range 25-52) with nonbacterial prostatitis in whom clinical management was unsuccessful in relieving the symptoms or signs of prostatitis were treated using TUNA. Read More

View Article

Download full-text PDF

Source
February 2002
3 Reads

The effect of transurethral needle ablation on symptoms of chronic pelvic pain syndrome--a pilot study.

Scand J Urol Nephrol 2001 Apr;35(2):127-31

Department of Urology, Kuopio University Hospital, Finland.

Objective: We evaluated the effects of transurethral needle ablation (TUNA) in chronic pelvic pain syndrome (CPPS).

Material And Methods: CPPS patients were subjected to TUNA (n = 21) or sham therapy (urethrocystoscopy) (n = 6). Digital rectal examination and transrectal ultrasound were performed. Read More

View Article

Download full-text PDF

Source
April 2001
4 Reads

Long-term effects on BPH of medical and instrumental therapies.

Authors:
P Puppo

Eur Urol 2001 Mar;39 Suppl 6:2-6

Department of Urology, Galliera Hospital, Genoa, Italy.

A variety of methods are available that provide relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). This paper reviews approaches for assessing treatment outcomes, along with morbidity and long-term reintervention rates for different mechanical treatments. Symptom scores do not necessarily correlate with the severity of bladder outlet obstruction, whereas reintervention rates provide a reliable objective measure of long-term outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000052592DOI Listing
March 2001
3 Reads

Early experience with transurethral needle ablation of large prostates.

Can J Urol 1999 Feb;6(1):686-691

Division of Urology, Prostate Clinic, Department of Surgery, The University of British Columbia, Vancouver, British Columbia.

OBJECTIVE: To evaluate the safety and effectiveness of transurethral needle ablation (TUNA(R)) performed on benign hyperplastic prostates > 60 gms. Patients and methods: Ten patients with bilobar hyperplasia and without a large middle lobe received one TUNA(R) Treatment. The mean age was 67. Read More

View Article

Download full-text PDF

Source
February 1999
3 Reads

Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation.

Urol Int 2001 ;66(2):89-93

Clinica Urologica, Università degli Studi, Ospedale Generale Regionale Umberto I, Piazza Cappelli 1, I-60121 Ancona, Italy.

Background/aims: In this study we wanted to examine the effects that transurethral needle ablation (TUNA) might have on the urodynamic characteristics of bladder outlet obstruction and to evaluate the clinical changes and the safety profile in patients undergoing the TUNA procedure, including the effects on erectile and ejaculatory function.

Materials And Methods: We evaluated 24 patients, aged between 66 and 81 (mean 73.4) years with a mean prostatic volume of 57 +/- 15 ml. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/56577
Publisher Site
http://dx.doi.org/10.1159/000056577DOI Listing
July 2001
4 Reads

[Transvesical radiofrequency needle ablation on prostatic benign hyperplasia].

Urologiia 2000 Nov-Dec(6):34-7

Transurethral needle ablation (TUNA) of the prostate is an effective method of thermal treatment of patients with benign prostatic hyperplasia (BPH). Suprapubic transvesical access was used in order to extend indications for interstitial application of radiofrequency energy. Transvesical needle ablation (TVNA) was performed in 89 patients with BPH under conditions of chronic ischuria or in the presence of a suprapubic cystostoma. Read More

View Article

Download full-text PDF

Source
January 2001
3 Reads

Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials?

Eur Urol 2000 ;38 Suppl 1:7-17

Division of Urology, Department of Surgery, L'Aquila University School of Medicine, L'Aquila, Italy.

Objectives: This manuscript reviews the outcomes of invasive and minimally-invasive treatments of lower urinary tract symptoms due to prostatic enlargement.

Methods: The MEDLINE database was searched for Medical Subject headings and text words including prostatic hyperplasia, treatment, surgery, thermal treatments, thermotherapy, laser, TUNA and vaportrode. Data from both randomised and non-randomised controlled trials were considered. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/52397
Publisher Site
http://dx.doi.org/10.1159/000052397DOI Listing
July 2001
2 Reads